<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="223030">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179400</url>
  </required_header>
  <id_info>
    <org_study_id>2000-200</org_study_id>
    <nct_id>NCT00179400</nct_id>
  </id_info>
  <brief_title>Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone</brief_title>
  <official_title>The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <brief_summary>
    <textblock>
      Doctors are studying natural oils as potential therapies for type 2 diabetes. Animal studies
      have suggested promising results using EPA (found in fish oils) to improve insulin action
      and lower blood sugar levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PARTICIPATION INCLUDES: Participation in the studies includes taking study capsules for up
      to 21 days, keeping a meal diary, and up to four overnight hospital stays. During the
      hospital visits, an IV will be placed in each arm, and small amounts of muscle and fat
      tissue will be removed (with minimal discomfort).

      COMPENSATION: Compensation of $400 per study is provided (or up to $1,600 for completing all
      studies)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double-Blind</masking>
  </study_design_info>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone/EPA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 subjects with an A1c over 8.%

        Exclusion Criteria:

        Those with bleeding disorders including GERD, PUD, any GI bleeding; High blood pressure,
        and anyone with a history of Coronary Artery Disease or exertional chest pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meredith Hawkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 7, 2012</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
